跳至主要内容
临床试验/NCT02943707
NCT02943707Unknown2 期

Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.

Wenzhou Medical University1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2016年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
40
试验地点
1
主要终点
Change from baseline white blood cell at 6 months

研究概览

简要总结

This study evaluates the effect of autologous bone marrow stem cells infusion (ABMSCi) therapy for liver diseases.Treatment group will receive ABMSCi and drugs therapy ,while control group will only receive drugs therapy.

详细描述

  1. Autologous bone marrow stem cells (ABMSC) mobilization and harvest For harvesting more ABMSC, ABMSC mobilization is induced by recombinant human granulocyte colony stimulating factor (rhGCSF,Gran○R), administered subcutaneously at a dose of 300μg daily for three consecutive days before bone marrow puncture.

Bone marrow (160-200ml) of the patients is harvested from both posterior superior iliacs according to standard procedures under local anaesthesia and is collected in a plastic bag containing heparin. 2. Both treatment group and control group receive drugs therapy. 3. ABMSC separation and infusion ABMSC is separated and purified in a class 10,000 clean laboratory. After fat and bony particles are removed by filtration, collected cells are moved to a cell-processing device. The reagents adopt the method of negative cells collection. Take the cells which intended to remove as target cells, and carry out the removal step-by-step. On the basis of this method, red blood cells, blood platelets, blood plasma will be completely removed with part of white cells and lymphocytes being remarkably removed as well while all the stem cells / progenitor cells are being well retained.

The nucleated cell (white blood cell) count of final ABMSC is measured by an automated complete blood count instrument and flow cytometry analysis. The number of mononuclear cells is counted manually under a microscope by Wright-Giemsa stain method. Cell differentiation factor 34(CD34) positive cells were determined by flow cytometry analysis.

The time of ABMSC separation and purification is 2.5-3 hours. ABMSC is added to 10 ml saline and well mixed by shaking the vial gently. The catheter is pushed to reach the proper hepatic artery. The diameter of the catheter is 1.4mm, it is thin enough to easily been inserted to right gastric artery . The mixture of saline and ABMSC is infused into proper hepatic artery at uniform speed for about two minutes. The catheter is removed after the ABMSCi. 4. Statistical analysis - Categorical data are presented as absolute values and percentages, whereas continuous data are summarized as mean and Standard Deviation. Statistical analysis was performed using t-test for paired or unpaired samples. Time courses of measurements of liver function parameters were analyzed by repeated-measures ANOVA. The analysis is performed using the Statistic Package for Social Science (SPSS). All statistical analysis is based on two-tailed hypothesis tests with a significance level of p< 0.05.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Definite liver diseases (such as viral hepatitis, autoimmune liver diseases, fatty liver diseases, ect);
  • Active bone marrow hyperplasia showed by bone marrow biopsy before ABMSCi;
  • Age between 18 and 60 years;
  • Abnormal liver function.

排除标准

  • Enlisted for liver transplantation
  • Diagnosis of hepatocellular carcinoma or other cancers
  • Other severe medical disease, and acute infection
  • pregnant or nursing females,co-infections with HIV ,serious bacterial infection
  • other vital organ or system dysfunction
  • with severe complications of liver cirrhosis
  • hematological disorder

研究组 & 干预措施

treatment group: ABMSCi & drugs

Experimental

ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally

干预措施: Autologous bone marrow stem cells infusion (Procedure)

treatment group: ABMSCi & drugs

Experimental

ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally

干预措施: drugs such as Ursodeoxycholic Acid tablets (Drug)

control group: drugs

Active Comparator

drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally

干预措施: drugs such as Ursodeoxycholic Acid tablets (Drug)

结局指标

主要结局

Change from baseline white blood cell at 6 months

时间窗: baseline and 6 months after treatment

white blood cell (WBC)

Change from baseline platelet at 6 months

时间窗: baseline and 6 months after treatment

platelet (PLT)

Change from baseline alanine aminotransferase at 6 months

时间窗: baseline and 6 months after treatment

alanine aminotransferase (ALT)

Change from baseline total bilirubin at 6 months

时间窗: baseline and 6 months after treatment

total bilirubin (TBil)

Change from baseline direct bilirubin at 6 months

时间窗: baseline and 6 months after treatment

direct bilirubin (DBil)

Change from baseline total bile acid at 6 months

时间窗: baseline and 6 months after treatment

total bile acid (TBA)

Change from baseline albumin at 6 months

时间窗: baseline and 6 months after treatment

albumin (ALB)

Change from baseline aspartate aminotransferase at 6 months

时间窗: baseline and 6 months after treatment

aspartate aminotransferase (AST)

Change from baseline prothrombin time at 6 months

时间窗: baseline and 6 months after treatment

prothrombin time (PT),

Change from baseline international normalized ratio at 6 months

时间窗: baseline and 6 months after treatment

international normalized ratio (INR)

次要结局

  • Change from baseline liver density at 6 months(baseline and 6 months after treatment)
  • Change from baseline liver size at 6 months(baseline and 6 months after treatment)
  • Change from baseline spleen thickness at 6 months(baseline and 6 months after treatment)
  • Incidence of adverse events that are related to treatment(baseline and 6 months after treatment)
  • Number of participants that survive without developing disease(12 months after treatment)
  • Number of participants that survive with developing disease(12 months after treatment)
  • Number of participants that die after treatment(12 months after treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

yongping chen

Director,Clinical Research

Wenzhou Medical University

研究点 (1)

Loading locations...

相似试验